Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Teladoc Health, Inc.NYSE: TDOC

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $67.87M fell 3.0% year over year, behind the +4.5% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.

Context

  • Research & development amounted to 11.0% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.0% toward the trailing-twelve-month pace of +4.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67.87M-5.2% QoQ
Last fiscal yearDec 2025
$277.92M-9.6% YoY
LTMMar 2026
$320.12M+4.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.0%——
1 year-9.6%——
3-year CAGR-5.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
277.92M USD
Year-over-year change
-9.6%
4-year CAGR
-2.8%

Research & Development vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.5% is the 5th highest of 10, against a peer median of +1.0%.
  • Research & development amounts to 12.7% of revenue for TDOC, versus a peer median of 9.4%.
TDOC Competitors
Research & Development for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$320.12M USD+4.5%-5.9%12.7%
IMNMImmunome, Inc.LTM Sep 2026$236.54M USD+35.6%+95.7%—
NVCRNovoCure LimitedLTM Mar 2026$229.1M USD+8.2%+2.9%34.0%
SDGRSchrödinger, Inc.LTM Sep 2026$160.31M USD-11.5%+11.1%59.6%
PHVSPharvaris N.V.LTM Sep 2026€132.22M EUR+7.0%+29.5%—
PHRPhreesia, Inc.LTM Apr 2026$117.98M USD-1.9%+10.0%23.8%
OMCLOmnicell, Inc.LTM Mar 2026$89.67M USD+1.0%-5.8%7.3%
AZTAAzenta, Inc.LTM Sep 2026$37.92M USD+31.1%+3.7%6.1%
EVOEvotec SELTM Mar 2026€36.91M EUR-18.7%-1.0%5.0%
OMDAOmada HealthLTM Mar 2026$32.6M USD-8.9%+15.8%11.5%
PGNYProgyny, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding TDOC) —+1.0%+10.0%9.4%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.03B2.41B2.6B2.57B2.53B
Cost of Revenue650.26M743.99M760.03M751.27M771.59M
Gross Profit1.38B1.66B1.84B1.82B1.76B
Gross Margin68.0%69.1%70.8%70.8%69.5%
Research & Development311.88M333.63M348.52M307.27M277.92M
Selling, General & Admin1.11B1.3B1.37B1.35B1.09B
Operating Expenses1.65B15.32B2.09B2.84B2.02B
Depreciation & Amortization207.57M209.93M254.11M240.51M363.12M
EBITDA(31.42M)(7.54M)43.61M31.72M147.3M
EBITDA Margin-1.5%-0.3%1.7%1.2%5.8%
Operating Income(265.63M)(13.65B)(248.55M)(1.02B)(262.96M)
Operating Margin-13.1%-567.3%-9.6%-39.7%-10.4%
Interest Income776K12.67M46.78M57.07M36.77M
Interest Expense81.14M21.94M22.28M23.8M19.71M
Other Income / Expenses(119.03M)(10.13M)28.95M27.23M27.43M
Income Before Tax(384.66M)(13.66B)(219.61M)(993.65M)(235.53M)
Pre-Tax Margin-18.9%-567.7%-8.4%-38.7%-9.3%
Income Tax Expense44.14M(3.81M)760K7.59M(35.21M)
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Net Margin-21.1%-567.5%-8.5%-39.0%-7.9%
EPS (Basic)(2.73)(84.60)(1.36)(5.87)(1.14)
EPS (Diluted)(2.73)(84.60)(1.34)(5.87)(1.14)
Weighted Avg Shares156.94M161.46M162.17M170.56M176.22M
Weighted Avg Shares (Diluted)156.94M161.46M164.58M170.56M176.22M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.